Janssen
Janssen Biotech is paying refunds for overcharges on certain 340B drugs purchased in the third quarter of 2020.

Janssen Issuing Refunds for 340B Overcharges

Drug manufacturer Janssen Biotech recently determined that it owes or may owe refunds to some 340B covered entities. The refunds [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer